English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Editors’ Note: Hung argues that the association between the HLA-B*1502 genotype and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) differs depending on whether patients are taking carbamazepine vs phenytoin and that cost estimates for the long-term sequelae of SJS/TEN are overlooked in the study by Dong et al. The authors explain the rationale of considering both drugs together and why the high cost of SJS/TEN treatment makes genotyping cost-effective. Droogsma and colleagues identify a potential selection bias in the study by Pariente et al., “Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors,” and suggest that clinicians should not discontinue treatment too readily as this may affect cognition. Chafic Karam, MD, and Robert C. Griggs, MD

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore